Evoke Pharma (NASDAQ:EVOK) Coverage Initiated by Analysts at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research report issued to clients and investors on Thursday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Stock Down 0.5 %

Shares of EVOK opened at $4.37 on Thursday. The stock has a market cap of $6.51 million, a price-to-earnings ratio of -0.40 and a beta of 0.36. Evoke Pharma has a 12 month low of $3.54 and a 12 month high of $17.40. The company has a 50-day moving average price of $5.15 and a two-hundred day moving average price of $5.43.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Evoke Pharma stock. Corsair Capital Management L.P. bought a new stake in Evoke Pharma, Inc. (NASDAQ:EVOK) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned about 1.42% of Evoke Pharma at the end of the most recent quarter.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.